CAR T
Published on December 26, 2024
Radiomic cytoreduction and bridging therapy to predict outcomes after CAR T-cell therapy in LBCL
by AACR
Hubbeling H, Leithner D, Silverman EA, et al. Metabolic Tumor Volume Response After Bridging Therapy Determines Chimeric Antigen Receptor T-Cell Outcomes in Large B-Cell Lymphoma. Clinical Cancer Research. 2024; (doi: 10.1158/1078-0432.CCR-24-0830).
Patients with high tumor burden are predisposed to less favorable outcomes after chimeric antigen receptor T-cell (CAR T) therapy, but researchers say radiomic cytoreduction achieved during bridging therapy (BT) can improve their prognosis. For the study, participants underwent PET scans to measure metabolic tumor volume (MTV) prior to leukapheresis and again in the period after BT but before CAR infusion. Based on a cut-off value of 65.4cc, disease burden was classified as high or low at both intervals. Among 144 participants who received BT, 56% registered a lower MTV following BT. Analysis showed that patients whose MTV dropped from high to low after BT achieved progression-free survival on par with that of participants whose values were low initially and remained low after bridging.
Read More
![]()